IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Bought by Wealthspire Advisors LLC

Wealthspire Advisors LLC raised its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 39.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,457 shares of the company’s stock after acquiring an additional 692 shares during the quarter. Wealthspire Advisors LLC’s holdings in IDEXX Laboratories were worth $1,364,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in IDXX. OFI Invest Asset Management purchased a new position in shares of IDEXX Laboratories during the 3rd quarter worth $25,000. Valley National Advisers Inc. boosted its holdings in IDEXX Laboratories by 84.6% during the 4th quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock valued at $26,000 after acquiring an additional 22 shares during the period. Geo Capital Gestora de Recursos Ltd purchased a new position in IDEXX Laboratories during the 3rd quarter valued at about $28,000. Covestor Ltd boosted its stake in shares of IDEXX Laboratories by 71.8% in the 3rd quarter. Covestor Ltd now owns 67 shares of the company’s stock valued at $29,000 after buying an additional 28 shares during the period. Finally, Whittier Trust Co. of Nevada Inc. boosted its stake in shares of IDEXX Laboratories by 108.6% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 73 shares of the company’s stock valued at $32,000 after buying an additional 38 shares during the period. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Up 2.8 %

Shares of NASDAQ IDXX traded up $13.75 on Thursday, hitting $500.82. The company had a trading volume of 546,581 shares, compared to its average volume of 445,009. IDEXX Laboratories, Inc. has a 12-month low of $372.50 and a 12-month high of $583.39. The business has a 50 day moving average of $517.91 and a two-hundred day moving average of $514.15. The company has a quick ratio of 1.16, a current ratio of 1.57 and a debt-to-equity ratio of 0.40. The firm has a market capitalization of $41.36 billion, a P/E ratio of 48.48, a PEG ratio of 3.78 and a beta of 1.27.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Monday, February 5th. The company reported $2.32 EPS for the quarter, beating analysts’ consensus estimates of $2.12 by $0.20. The firm had revenue of $901.60 million during the quarter, compared to the consensus estimate of $891.88 million. IDEXX Laboratories had a return on equity of 63.66% and a net margin of 23.26%. IDEXX Laboratories’s revenue for the quarter was up 8.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.05 earnings per share. As a group, equities research analysts forecast that IDEXX Laboratories, Inc. will post 11.05 earnings per share for the current fiscal year.

Analyst Ratings Changes

IDXX has been the topic of several research analyst reports. JPMorgan Chase & Co. raised their target price on IDEXX Laboratories from $600.00 to $630.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Thursday, May 2nd. The Goldman Sachs Group lifted their price target on IDEXX Laboratories from $500.00 to $650.00 and gave the company a “buy” rating in a research note on Wednesday, January 17th. William Blair reissued an “outperform” rating on shares of IDEXX Laboratories in a report on Tuesday, April 9th. Finally, Piper Sandler cut IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price target for the company. in a report on Tuesday, January 30th. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $580.88.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.